Cargando…

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure()

OBJECTIVE: Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients. Novel treatment strategies are demanded after conventional treatment failure. This was a prospective, single-arm, and si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, ChuanLiang, Zhou, Li, Lian, Bin, Si, Lu, Sheng, XiNan, Chi, ZhiHong, Kong, Yan, Wang, Xuan, Tang, BiXia, Mao, LiLi, Li, SiMing, Dai, Jie, Yan, XieQiao, Bai, Xue, Guo, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080644/ https://www.ncbi.nlm.nih.gov/pubmed/30056366 http://dx.doi.org/10.1016/j.tranon.2018.07.009

Ejemplares similares

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
por: Zhou, Li, et al.
Publicado: (2021)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients
por: Wang, Xuan, et al.
Publicado: (2019)

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study
por: Wei, Xiaoting, et al.
Publicado: (2019)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma
por: Dai, Jie, et al.
Publicado: (2020)

A nomogram incorporating Ki67 to predict survival of acral melanoma
por: Du, Yu, et al.
Publicado: (2023)

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
por: Cui, ChuanLiang, et al.
Publicado: (2022)

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study
por: Zhou, Li, et al.
Publicado: (2022)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials
por: Bai, Xue, et al.
Publicado: (2021)

Surgical Outcomes of Vaginal or Cervical Melanoma
por: Tian, Hui, et al.
Publicado: (2022)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
por: Mao, Lili, et al.
Publicado: (2021)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
por: Tang, Bixia, et al.
Publicado: (2019)

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
por: Sheng, Xinan, et al.
Publicado: (2019)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
por: Ma, Meng, et al.
Publicado: (2019)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: Erratum
por: Ma, Meng, et al.
Publicado: (2022)

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
por: Chi, Zhihong, et al.
Publicado: (2011)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon
por: Yu, Jiayi, et al.
Publicado: (2017)

Apatinib and temozolomide in children with recurrent ependymoma: A case report
por: Zhao, Shuangshuang, et al.
Publicado: (2022)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma
por: Dai, Jie, et al.
Publicado: (2017)

Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy
por: Luo, Cong, et al.
Publicado: (2017)

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma
por: Yu, Sifan, et al.
Publicado: (2018)

Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma
por: Wang, Chao, et al.
Publicado: (2018)

Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study
por: Wei, Xiaoting, et al.
Publicado: (2022)

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
por: Wu, Xiaowen, et al.
Publicado: (2017)

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
por: Cui, Chuanliang, et al.
Publicado: (2021)

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
por: Yu, Huan, et al.
Publicado: (2017)

Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019)

Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report
por: Zhao, Mingming, et al.
Publicado: (2022)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
por: Yu, Jiayi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h4k3bljj77kjo6iqnd208kasos